IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiat., Calambrone (Pisa), Italy.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Curr Neuropharmacol. 2023;21(4):911-934. doi: 10.2174/1570159X20666220706104117.
Bipolar Disorder (BD) is a highly comorbid condition, and rates of cooccurring disorders are even higher in youth. Comorbid disorders strongly affect clinical presentation, natural course, prognosis, and treatment.
This review focuses on the clinical and treatment implications of the comorbidity between BD and Attention-Deficit/Hyperactivity Disorder, disruptive behavior disorders (Oppositional Defiant Disorder and/or Conduct Disorder), alcohol and substance use disorders, Autism Spectrum Disorder, anxiety disorders, Obsessive-Compulsive Disorder, and eating disorders.
These associations define specific conditions which are not simply a sum of different clinical pictures, but occur as distinct and complex combinations with specific developmental pathways over time and selective therapeutic requirements. Pharmacological treatments can improve these clinical pictures by addressing the comorbid conditions, though the same treatments may also worsen BD by inducing manic or depressive switches.
The timely identification of BD comorbidities may have relevant clinical implications in terms of symptomatology, course, treatment and outcome. Specific studies addressing the pharmacological management of BD and comorbidities are still scarce, and information is particularly lacking in children and adolescents; for this reason, the present review also included studies conducted on adult samples. Developmentally-sensitive controlled clinical trials are thus warranted to improve the prognosis of these highly complex patients, requiring timely and finely personalized therapies.
双相情感障碍(BD)是一种高度共病的疾病,且共病障碍的发生率在年轻人中更高。共病障碍强烈影响临床表型、自然病程、预后和治疗。
本综述重点关注 BD 与注意力缺陷/多动障碍、破坏性行为障碍(对立违抗性障碍和/或品行障碍)、酒精和物质使用障碍、自闭症谱系障碍、焦虑障碍、强迫症和饮食障碍之间的共病的临床和治疗意义。
这些关联定义了特定的情况,它们不仅仅是不同临床特征的简单总和,而是随着时间的推移以特定的发展途径和特定的治疗需求出现的独特而复杂的组合。药物治疗可以通过治疗共病来改善这些临床特征,但相同的治疗也可能通过诱导躁狂或抑郁发作而使 BD 恶化。
及时识别 BD 共病可能对症状、病程、治疗和预后具有重要的临床意义。专门针对 BD 及共病的药物治疗管理的研究仍然很少,而儿童和青少年的信息尤其缺乏;出于这个原因,本综述还包括了对成年样本进行的研究。因此,有必要进行针对这些高度复杂患者的、具有发展敏感性的对照临床试验,以改善这些患者的预后,需要及时和精细的个体化治疗。